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ABSTRACT:
Devic’s disease or syndrome also known as Neuromyelitis optica (NMO) which is a demyelinating central nervous 
system (immune-mediated) ailment that predominantly targets the optic nerves and spinal cord. NMO-IgG 
seropositivity & longitudinally extensive  spinal-cord lesions typically represents the Devic’s disease & differentiates it 
from Multiple Sclerosis (MS).Treatment for NMO is based upon its presentation such as for acute phase(steroids, IVIG 
etc), prevention of relapse (steroid sparing immunosuppression etc) and symptom based therapy (e.g spasticity etc). 
Here, we present a case of NMO in a young female (26 years old), married patient who presented to us with total vision 
loss, urinary & fecal incontinence & paraplegia. She was being treated as a case of Multiple Sclerosis (MS) several 
years ago but we further investigated & found NMO-IgG seropositivity and other findings in the history that conforms 
the diagnostic criteria of NMOSD for this patient. Furthermore, the patient was treated with IV glucocorticoids for its 
acute phase of disease & sent home when symptoms of transverse myelitis improved.
KEYWORDS:  Neuromyelitis optica (NMO), Multiple Sclerosis (MS), Neuromyelitis optica-immunoglobulinG(NMO-IgG), 
aquaporin-4 antibody(AQP4-Ab), Cranial nerve(CN)
INTRODUCTION:
Neuromyelitis optica (a demyelinating  disease of central nervous system)1was described by Albutt in 1870 and after 
two decades Devic narrated its clinical features i.e. acute transverse myelitis &optic neuritis. The incidence 
&prevalence of NMO is quite low as it is a rare disease to be found in general population. The worldwide incidence of 
this disease is 0.053 to 0.40 per 100,000, while the prevalence is ranged from 0.52 to 4.4 per 100,0002 .This 
disease (NMO) is more to be found among Asians, Blacks & Indian populations & it is estimated that the prevalence 
in Northwest of England is approximately  0.72 per 100,0003 & in Japan is 14 per 100,0004,5 While the mean age for 
NMO is 40 years(approx.) but it could be present among young ones6,7 & there is a female predominance with a female 
to male ratio of3:1. Neuromyelitis optica-immunoglobulin is a highly specific & sensitive auto antibody for diagnosis of 
NMO which binds to the aquaporin-4 (AQP4); channels that regulate water homeostasis in the CNS4,7,8. 
 
CASE REPORT:
A 26 year old female, married having two children (a girl & boy) presented to us with bilateral vision loss (total 
blindness) for the last 6 years(2012-18), paraplegia for the last 2 months(2018) with urinary & fecal incontinence 
(on/off). There was sudden loss of vision in the right eye with extreme pain  9 years ago(2010), followed by other eye 
vision loss after 3 years of the previous one but this time it was a gradual loss of sight over 2-3 months. In the same 
year she had her first episode of leg weakness (left) & urinary incontinence which was gradual & slow in nature but 
improved after 1 month of hospital treatment (drugs included steroids). After 3 years(2013) she felt moderate 
weakness in both upper limbs and left leg weakness with urinary & fecal incontinence. It was gradual in onset & power 
was much reduced according to the patient. It took almost 6 months to improve back to normal again after a hospital 
treatment (diagnosed as MS patient about 7 years ago & was treated in hospital as accordingly but not recovered 
according to patient’s history). Now, she presented to us with the above stated symptoms for the last 2 months which 
are worsening each day. There was no other significant medical history of any other disease previously but she had 2 
cesarean sections for both of her deliveries. In her personal history she denied of taking any kind of drugs, smoking or 
alcohol intake. Her sleep is normal but appetite is decreased & there is urinary & fecal incontinence.Her family history 
was normal and insignificant regarding  neurological diseases. Her physical examination revealed normal vitals 
state(Pulse80/min, B.P130/70, Temp98.6F & there was no lyphmadenophathy, jaundice, edema or cyanosis in body). 
The Mental state examination was evaluated & found completely normal as she was alert, attentive, and oriented in 
time, place & person. Speech was clear and fluent with good repetition, comprehension, and naming.Eye examination 
showed bilateral optic disc atrophy & there was no light perception(fixed dilated pupils) but movements were normal & 
there was no sign of ptosisor deviation of eyes. CN V examination showed facial sensation was intact to pinprick in all 
3 divisions bilaterally & corneal responses were intact. Similarly,
TABLE NO.1 EXAMIANTION OF MOTOR SYSTEM  
All other systems including cardiovascular, respiratory & abdominal were normal & there was no clinical 
symptomatology /findings found related to these systems (except urinary incontinence). Her lab investigations showed 
leucocytosis (12500/mm3), raised ESR levels(70mm/hr) & CRP levels(4.5mg/l). Other investigations like renal 
function tests, liver function tests, serum electrolytes & serum glucose were in normal limits. ECG & Echocardiography 
was done and it was also normal showed nothing of peculiar importance. MRI brain & spine(with contrast) was advised 
to the patient for Bilteral optic neuritis and TM which favors NMO more than MS but MRI brain was unequivocal & 
showed no lesions in brain infact there was Longitudinally extensive transverse myelitis (large area of abnormal signals 
noted  in the spinal cord at the level of T2 through T6 vertebrae with unrestricted diffusion & cord thinning).In our 
patient, a MRI done 5-6 years back had lesion around 3rd ventricle that are totally vanished now (normal MRI Brain). 
This led to the  diagnosis of NMO as she was meeting the diagnostic criteria of NMO[table.2]1 so, the aquaporin-4 
antibody(AQP4-Ab) was sent for the confirmation of Devic’s disease & it came back positive(1385.5U/ml)ref 
range(0.0-0.3U/ml). Thus this established our diagnosis of NMO as per its criteria (100%) over Multiple Sclerosis1. As, 
she presented to us with an acute phase of NMO so we started her on IV glucocorticoids (methyl-prednisolone) 500mg 
diluted once a day for 7 days, injection Enoxaparin sodium(40mg) once a day for the prophylaxis of deep venous 
thrombosis, injection ceftrioxone 1gm(for leucocytosis) & IV proton pump inhibitors. She remained  admitted in 
hospital for 8 days and then was discharged on immunosuppressive drug (tab. Azathioprine) for the prevention of 
future relapses of this disease. The displaying side effects were very little enhanced aside from urinary/fecal 
incontinence and she was likewise exhorted physiotherapy (for development of leg weakness) & she requested line up 
following multi month with 2 weekly rehashing of renal and liver capacity tests.
DISCUSSION: 
Devic’s disease or Neuromyelitis optica is an inflammatory & demyelinating disease of central nervous system1 having 
typical cardinal clinical characteristics i.e. Longitudinally extensive transverse myelitis & optic neuritis. The  previously 
stated features can be present at the same time or can be separated by many years. Diseases like multiple sclerosis 
,malignancy , neurosarcoidosis, infections, inflammation, idiopathic optic neuritis, idiopathic transverse myelitis or 
vascular diseases can mimic NMOSD by involving optic nerve or spinal cord. NMO and MS  share some phenotypic 
features & it should be differentiated from each other as they have different treatment modalities.(Table no.3)9.So 
optic involvement, no MRI brain lesions, spinal cord lesions >3segments and positive AQP4-Ab, were all Confirmatory 
of NMO. Differentiation of NMO from MS is important as interferons, fingolimod and natalizumab are ineffective or may 
aggravate NMO10. Idiopathic optic neuritis is excluded from differentials because it is usually unilateral with impaired 
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color vision but improvement of visual acuity with 3 weeks to 1year11.In our case, relapsing disease course,bilateral 
optic nerve involvement, poor visual outcome & transverse myelitis causing  paraplegia with urinary incontinence are 
the prominent features.
Table2 International consensus diagnostic criteria for Neuromyelitis Optica(2015) [1]
Table3 Comparison between MS & NMO9 .
According to the International consensus diagnostic criteria for Neuromyelitis Optica (2015)[table no.2]1 our patient 
has positive aquaporin-4 antibody(AQP4-Ab) and has 2 core clinical characteristics which confirms the diagnosis. 
NMO can be monophasic  i.e. a single episode with permanent remission or it can result in a relapsing disease which 
is present in 85-90% of the cases. The characteristics of both monophasic & relapsing NMO have quite 
dissimilarities.[table no.4]6
Table 4 Characteristics of monophasic and relapsing Neuromyelitis optica[6]
Identification of NMO is by neurological examination, blood test(positive anti AQP4-Ab),MRI,CSF findings .Here 
auto-antibodies develop against aquaporin 4(water channel protein) and there is disruption of blood–brain barrier, 
glutamate homeostasis impairment and induction of necrotic cell death by AQP4-Ab-positive serum10.this leads to 
astrocyte damage, perivascular and spinal cord inflammation and cavitations of optic nerve12.AQP4-IgG is 
73%sensitive and 91% specific in NMO12.NMO is a disease with severe sequelae so acute and maintenance therapy 
both are very important. In acute cases, pulse steroid therapy is given. If response is not good, IVIG and 
plasmapheresis may play a role12for long term relapse prevention, Azathioprine with oral steroids and mycophenolate 
mofetil with oral steroids are given13.For refractory cases, Rituximab and mitoxantrone show some efficacy13.There 
is no role of interferons10.In our case patient showed improvement with 7 days IV steroids and then discharged on 
Azathioprine as maintenance therapy. As we had advised patient for follow up & she came with same presentation at 
which she was discahrged after 1 month. We ran all her baseline investigations(Cbc, Rft, Lft, Serum electrolytes & 
urine/RE) & they came in normal parameters. To sum up, 5 year survival of NMO is as low as 68%13.
 
CONCLUSION:
 
After all this inferencing we emphasize early and right diagnosis with management of acute and chronic phase as 
damage & disability is slowly cumulative by recurrent attacks that damage new areas of myelin. we also need attention 
to significance of strict patient-physician collaboration in follow-up-periods. 
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according to patient’s history). Now, she presented to us with the above stated symptoms for the last 2 months which 
are worsening each day. There was no other significant medical history of any other disease previously but she had 2 
cesarean sections for both of her deliveries. In her personal history she denied of taking any kind of drugs, smoking or 
alcohol intake. Her sleep is normal but appetite is decreased & there is urinary & fecal incontinence.Her family history 
was normal and insignificant regarding  neurological diseases. Her physical examination revealed normal vitals 
state(Pulse80/min, B.P130/70, Temp98.6F & there was no lyphmadenophathy, jaundice, edema or cyanosis in body). 
The Mental state examination was evaluated & found completely normal as she was alert, attentive, and oriented in 
time, place & person. Speech was clear and fluent with good repetition, comprehension, and naming.Eye examination 
showed bilateral optic disc atrophy & there was no light perception(fixed dilated pupils) but movements were normal & 
there was no sign of ptosisor deviation of eyes. CN V examination showed facial sensation was intact to pinprick in all 
3 divisions bilaterally & corneal responses were intact. Similarly,
TABLE NO.1 EXAMIANTION OF MOTOR SYSTEM  
All other systems including cardiovascular, respiratory & abdominal were normal & there was no clinical 
symptomatology /findings found related to these systems (except urinary incontinence). Her lab investigations showed 
leucocytosis (12500/mm3), raised ESR levels(70mm/hr) & CRP levels(4.5mg/l). Other investigations like renal 
function tests, liver function tests, serum electrolytes & serum glucose were in normal limits. ECG & Echocardiography 
was done and it was also normal showed nothing of peculiar importance. MRI brain & spine(with contrast) was advised 
to the patient for Bilteral optic neuritis and TM which favors NMO more than MS but MRI brain was unequivocal & 
showed no lesions in brain infact there was Longitudinally extensive transverse myelitis (large area of abnormal signals 
noted  in the spinal cord at the level of T2 through T6 vertebrae with unrestricted diffusion & cord thinning).In our 
patient, a MRI done 5-6 years back had lesion around 3rd ventricle that are totally vanished now (normal MRI Brain). 
This led to the  diagnosis of NMO as she was meeting the diagnostic criteria of NMO[table.2]1 so, the aquaporin-4 
antibody(AQP4-Ab) was sent for the confirmation of Devic’s disease & it came back positive(1385.5U/ml)ref 
range(0.0-0.3U/ml). Thus this established our diagnosis of NMO as per its criteria (100%) over Multiple Sclerosis1. As, 
she presented to us with an acute phase of NMO so we started her on IV glucocorticoids (methyl-prednisolone) 500mg 
diluted once a day for 7 days, injection Enoxaparin sodium(40mg) once a day for the prophylaxis of deep venous 
thrombosis, injection ceftrioxone 1gm(for leucocytosis) & IV proton pump inhibitors. She remained  admitted in 
hospital for 8 days and then was discharged on immunosuppressive drug (tab. Azathioprine) for the prevention of 
future relapses of this disease. The displaying side effects were very little enhanced aside from urinary/fecal 
incontinence and she was likewise exhorted physiotherapy (for development of leg weakness) & she requested line up 
following multi month with 2 weekly rehashing of renal and liver capacity tests.
DISCUSSION: 
Devic’s disease or Neuromyelitis optica is an inflammatory & demyelinating disease of central nervous system1 having 
typical cardinal clinical characteristics i.e. Longitudinally extensive transverse myelitis & optic neuritis. The  previously 
stated features can be present at the same time or can be separated by many years. Diseases like multiple sclerosis 
,malignancy , neurosarcoidosis, infections, inflammation, idiopathic optic neuritis, idiopathic transverse myelitis or 
vascular diseases can mimic NMOSD by involving optic nerve or spinal cord. NMO and MS  share some phenotypic 
features & it should be differentiated from each other as they have different treatment modalities.(Table no.3)9.So 
optic involvement, no MRI brain lesions, spinal cord lesions >3segments and positive AQP4-Ab, were all Confirmatory 
of NMO. Differentiation of NMO from MS is important as interferons, fingolimod and natalizumab are ineffective or may 
aggravate NMO10. Idiopathic optic neuritis is excluded from differentials because it is usually unilateral with impaired 
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color vision but improvement of visual acuity with 3 weeks to 1year11.In our case, relapsing disease course,bilateral 
optic nerve involvement, poor visual outcome & transverse myelitis causing  paraplegia with urinary incontinence are 
the prominent features.
Table2 International consensus diagnostic criteria for Neuromyelitis Optica(2015) [1]
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Table3 Comparison between MS & NMO9 .
According to the International consensus diagnostic criteria for Neuromyelitis Optica (2015)[table no.2]1 our patient 
has positive aquaporin-4 antibody(AQP4-Ab) and has 2 core clinical characteristics which confirms the diagnosis. 
NMO can be monophasic  i.e. a single episode with permanent remission or it can result in a relapsing disease which 
is present in 85-90% of the cases. The characteristics of both monophasic & relapsing NMO have quite 
dissimilarities.[table no.4]6
Table 4 Characteristics of monophasic and relapsing Neuromyelitis optica[6]
Identification of NMO is by neurological examination, blood test(positive anti AQP4-Ab),MRI,CSF findings .Here 
auto-antibodies develop against aquaporin 4(water channel protein) and there is disruption of blood–brain barrier, 
glutamate homeostasis impairment and induction of necrotic cell death by AQP4-Ab-positive serum10.this leads to 
astrocyte damage, perivascular and spinal cord inflammation and cavitations of optic nerve12.AQP4-IgG is 
73%sensitive and 91% specific in NMO12.NMO is a disease with severe sequelae so acute and maintenance therapy 
both are very important. In acute cases, pulse steroid therapy is given. If response is not good, IVIG and 
plasmapheresis may play a role12for long term relapse prevention, Azathioprine with oral steroids and mycophenolate 
mofetil with oral steroids are given13.For refractory cases, Rituximab and mitoxantrone show some efficacy13.There 
is no role of interferons10.In our case patient showed improvement with 7 days IV steroids and then discharged on 
Azathioprine as maintenance therapy. As we had advised patient for follow up & she came with same presentation at 
which she was discahrged after 1 month. We ran all her baseline investigations(Cbc, Rft, Lft, Serum electrolytes & 
urine/RE) & they came in normal parameters. To sum up, 5 year survival of NMO is as low as 68%13.
 
CONCLUSION:
 
After all this inferencing we emphasize early and right diagnosis with management of acute and chronic phase as 
damage & disability is slowly cumulative by recurrent attacks that damage new areas of myelin. we also need attention 
to significance of strict patient-physician collaboration in follow-up-periods. 
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ABSTRACT:
Devic’s disease or syndrome also known as Neuromyelitis optica (NMO) which is a demyelinating central nervous 
system (immune-mediated) ailment that predominantly targets the optic nerves and spinal cord. NMO-IgG 
seropositivity & longitudinally extensive  spinal-cord lesions typically represents the Devic’s disease & differentiates it 
from Multiple Sclerosis (MS).Treatment for NMO is based upon its presentation such as for acute phase(steroids, IVIG 
etc), prevention of relapse (steroid sparing immunosuppression etc) and symptom based therapy (e.g spasticity etc). 
Here, we present a case of NMO in a young female (26 years old), married patient who presented to us with total vision 
loss, urinary & fecal incontinence & paraplegia. She was being treated as a case of Multiple Sclerosis (MS) several 
years ago but we further investigated & found NMO-IgG seropositivity and other findings in the history that conforms 
the diagnostic criteria of NMOSD for this patient. Furthermore, the patient was treated with IV glucocorticoids for its 
acute phase of disease & sent home when symptoms of transverse myelitis improved.
KEYWORDS:  Neuromyelitis optica (NMO), Multiple Sclerosis (MS), Neuromyelitis optica-immunoglobulinG(NMO-IgG), 
aquaporin-4 antibody(AQP4-Ab), Cranial nerve(CN)
INTRODUCTION:
Neuromyelitis optica (a demyelinating  disease of central nervous system)1was described by Albutt in 1870 and after 
two decades Devic narrated its clinical features i.e. acute transverse myelitis &optic neuritis. The incidence 
&prevalence of NMO is quite low as it is a rare disease to be found in general population. The worldwide incidence of 
this disease is 0.053 to 0.40 per 100,000, while the prevalence is ranged from 0.52 to 4.4 per 100,0002 .This 
disease (NMO) is more to be found among Asians, Blacks & Indian populations & it is estimated that the prevalence 
in Northwest of England is approximately  0.72 per 100,0003 & in Japan is 14 per 100,0004,5 While the mean age for 
NMO is 40 years(approx.) but it could be present among young ones6,7 & there is a female predominance with a female 
to male ratio of3:1. Neuromyelitis optica-immunoglobulin is a highly specific & sensitive auto antibody for diagnosis of 
NMO which binds to the aquaporin-4 (AQP4); channels that regulate water homeostasis in the CNS4,7,8. 
 
CASE REPORT:
A 26 year old female, married having two children (a girl & boy) presented to us with bilateral vision loss (total 
blindness) for the last 6 years(2012-18), paraplegia for the last 2 months(2018) with urinary & fecal incontinence 
(on/off). There was sudden loss of vision in the right eye with extreme pain  9 years ago(2010), followed by other eye 
vision loss after 3 years of the previous one but this time it was a gradual loss of sight over 2-3 months. In the same 
year she had her first episode of leg weakness (left) & urinary incontinence which was gradual & slow in nature but 
improved after 1 month of hospital treatment (drugs included steroids). After 3 years(2013) she felt moderate 
weakness in both upper limbs and left leg weakness with urinary & fecal incontinence. It was gradual in onset & power 
was much reduced according to the patient. It took almost 6 months to improve back to normal again after a hospital 
treatment (diagnosed as MS patient about 7 years ago & was treated in hospital as accordingly but not recovered 
according to patient’s history). Now, she presented to us with the above stated symptoms for the last 2 months which 
are worsening each day. There was no other significant medical history of any other disease previously but she had 2 
cesarean sections for both of her deliveries. In her personal history she denied of taking any kind of drugs, smoking or 
alcohol intake. Her sleep is normal but appetite is decreased & there is urinary & fecal incontinence.Her family history 
was normal and insignificant regarding  neurological diseases. Her physical examination revealed normal vitals 
state(Pulse80/min, B.P130/70, Temp98.6F & there was no lyphmadenophathy, jaundice, edema or cyanosis in body). 
The Mental state examination was evaluated & found completely normal as she was alert, attentive, and oriented in 
time, place & person. Speech was clear and fluent with good repetition, comprehension, and naming.Eye examination 
showed bilateral optic disc atrophy & there was no light perception(fixed dilated pupils) but movements were normal & 
there was no sign of ptosisor deviation of eyes. CN V examination showed facial sensation was intact to pinprick in all 
3 divisions bilaterally & corneal responses were intact. Similarly,
TABLE NO.1 EXAMIANTION OF MOTOR SYSTEM  
All other systems including cardiovascular, respiratory & abdominal were normal & there was no clinical 
symptomatology /findings found related to these systems (except urinary incontinence). Her lab investigations showed 
leucocytosis (12500/mm3), raised ESR levels(70mm/hr) & CRP levels(4.5mg/l). Other investigations like renal 
function tests, liver function tests, serum electrolytes & serum glucose were in normal limits. ECG & Echocardiography 
was done and it was also normal showed nothing of peculiar importance. MRI brain & spine(with contrast) was advised 
to the patient for Bilteral optic neuritis and TM which favors NMO more than MS but MRI brain was unequivocal & 
showed no lesions in brain infact there was Longitudinally extensive transverse myelitis (large area of abnormal signals 
noted  in the spinal cord at the level of T2 through T6 vertebrae with unrestricted diffusion & cord thinning).In our 
patient, a MRI done 5-6 years back had lesion around 3rd ventricle that are totally vanished now (normal MRI Brain). 
This led to the  diagnosis of NMO as she was meeting the diagnostic criteria of NMO[table.2]1 so, the aquaporin-4 
antibody(AQP4-Ab) was sent for the confirmation of Devic’s disease & it came back positive(1385.5U/ml)ref 
range(0.0-0.3U/ml). Thus this established our diagnosis of NMO as per its criteria (100%) over Multiple Sclerosis1. As, 
she presented to us with an acute phase of NMO so we started her on IV glucocorticoids (methyl-prednisolone) 500mg 
diluted once a day for 7 days, injection Enoxaparin sodium(40mg) once a day for the prophylaxis of deep venous 
thrombosis, injection ceftrioxone 1gm(for leucocytosis) & IV proton pump inhibitors. She remained  admitted in 
hospital for 8 days and then was discharged on immunosuppressive drug (tab. Azathioprine) for the prevention of 
future relapses of this disease. The displaying side effects were very little enhanced aside from urinary/fecal 
incontinence and she was likewise exhorted physiotherapy (for development of leg weakness) & she requested line up 
following multi month with 2 weekly rehashing of renal and liver capacity tests.
DISCUSSION: 
Devic’s disease or Neuromyelitis optica is an inflammatory & demyelinating disease of central nervous system1 having 
typical cardinal clinical characteristics i.e. Longitudinally extensive transverse myelitis & optic neuritis. The  previously 
stated features can be present at the same time or can be separated by many years. Diseases like multiple sclerosis 
,malignancy , neurosarcoidosis, infections, inflammation, idiopathic optic neuritis, idiopathic transverse myelitis or 
vascular diseases can mimic NMOSD by involving optic nerve or spinal cord. NMO and MS  share some phenotypic 
features & it should be differentiated from each other as they have different treatment modalities.(Table no.3)9.So 
optic involvement, no MRI brain lesions, spinal cord lesions >3segments and positive AQP4-Ab, were all Confirmatory 
of NMO. Differentiation of NMO from MS is important as interferons, fingolimod and natalizumab are ineffective or may 
aggravate NMO10. Idiopathic optic neuritis is excluded from differentials because it is usually unilateral with impaired 
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color vision but improvement of visual acuity with 3 weeks to 1year11.In our case, relapsing disease course,bilateral 
optic nerve involvement, poor visual outcome & transverse myelitis causing  paraplegia with urinary incontinence are 
the prominent features.
Table2 International consensus diagnostic criteria for Neuromyelitis Optica(2015) [1]
Table3 Comparison between MS & NMO9 .
According to the International consensus diagnostic criteria for Neuromyelitis Optica (2015)[table no.2]1 our patient 
has positive aquaporin-4 antibody(AQP4-Ab) and has 2 core clinical characteristics which confirms the diagnosis. 
NMO can be monophasic  i.e. a single episode with permanent remission or it can result in a relapsing disease which 
is present in 85-90% of the cases. The characteristics of both monophasic & relapsing NMO have quite 
dissimilarities.[table no.4]6
Table 4 Characteristics of monophasic and relapsing Neuromyelitis optica[6]
 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
Identification of NMO is by neurological examination, blood test(positive anti AQP4-Ab),MRI,CSF findings .Here 
auto-antibodies develop against aquaporin 4(water channel protein) and there is disruption of blood–brain barrier, 
glutamate homeostasis impairment and induction of necrotic cell death by AQP4-Ab-positive serum10.this leads to 
astrocyte damage, perivascular and spinal cord inflammation and cavitations of optic nerve12.AQP4-IgG is 
73%sensitive and 91% specific in NMO12.NMO is a disease with severe sequelae so acute and maintenance therapy 
both are very important. In acute cases, pulse steroid therapy is given. If response is not good, IVIG and 
plasmapheresis may play a role12for long term relapse prevention, Azathioprine with oral steroids and mycophenolate 
mofetil with oral steroids are given13.For refractory cases, Rituximab and mitoxantrone show some efficacy13.There 
is no role of interferons10.In our case patient showed improvement with 7 days IV steroids and then discharged on 
Azathioprine as maintenance therapy. As we had advised patient for follow up & she came with same presentation at 
which she was discahrged after 1 month. We ran all her baseline investigations(Cbc, Rft, Lft, Serum electrolytes & 
urine/RE) & they came in normal parameters. To sum up, 5 year survival of NMO is as low as 68%13.
 
CONCLUSION:
 
After all this inferencing we emphasize early and right diagnosis with management of acute and chronic phase as 
damage & disability is slowly cumulative by recurrent attacks that damage new areas of myelin. we also need attention 
to significance of strict patient-physician collaboration in follow-up-periods. 
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ABSTRACT:
Devic’s disease or syndrome also known as Neuromyelitis optica (NMO) which is a demyelinating central nervous 
system (immune-mediated) ailment that predominantly targets the optic nerves and spinal cord. NMO-IgG 
seropositivity & longitudinally extensive  spinal-cord lesions typically represents the Devic’s disease & differentiates it 
from Multiple Sclerosis (MS).Treatment for NMO is based upon its presentation such as for acute phase(steroids, IVIG 
etc), prevention of relapse (steroid sparing immunosuppression etc) and symptom based therapy (e.g spasticity etc). 
Here, we present a case of NMO in a young female (26 years old), married patient who presented to us with total vision 
loss, urinary & fecal incontinence & paraplegia. She was being treated as a case of Multiple Sclerosis (MS) several 
years ago but we further investigated & found NMO-IgG seropositivity and other findings in the history that conforms 
the diagnostic criteria of NMOSD for this patient. Furthermore, the patient was treated with IV glucocorticoids for its 
acute phase of disease & sent home when symptoms of transverse myelitis improved.
KEYWORDS:  Neuromyelitis optica (NMO), Multiple Sclerosis (MS), Neuromyelitis optica-immunoglobulinG(NMO-IgG), 
aquaporin-4 antibody(AQP4-Ab), Cranial nerve(CN)
INTRODUCTION:
Neuromyelitis optica (a demyelinating  disease of central nervous system)1was described by Albutt in 1870 and after 
two decades Devic narrated its clinical features i.e. acute transverse myelitis &optic neuritis. The incidence 
&prevalence of NMO is quite low as it is a rare disease to be found in general population. The worldwide incidence of 
this disease is 0.053 to 0.40 per 100,000, while the prevalence is ranged from 0.52 to 4.4 per 100,0002 .This 
disease (NMO) is more to be found among Asians, Blacks & Indian populations & it is estimated that the prevalence 
in Northwest of England is approximately  0.72 per 100,0003 & in Japan is 14 per 100,0004,5 While the mean age for 
NMO is 40 years(approx.) but it could be present among young ones6,7 & there is a female predominance with a female 
to male ratio of3:1. Neuromyelitis optica-immunoglobulin is a highly specific & sensitive auto antibody for diagnosis of 
NMO which binds to the aquaporin-4 (AQP4); channels that regulate water homeostasis in the CNS4,7,8. 
 
CASE REPORT:
A 26 year old female, married having two children (a girl & boy) presented to us with bilateral vision loss (total 
blindness) for the last 6 years(2012-18), paraplegia for the last 2 months(2018) with urinary & fecal incontinence 
(on/off). There was sudden loss of vision in the right eye with extreme pain  9 years ago(2010), followed by other eye 
vision loss after 3 years of the previous one but this time it was a gradual loss of sight over 2-3 months. In the same 
year she had her first episode of leg weakness (left) & urinary incontinence which was gradual & slow in nature but 
improved after 1 month of hospital treatment (drugs included steroids). After 3 years(2013) she felt moderate 
weakness in both upper limbs and left leg weakness with urinary & fecal incontinence. It was gradual in onset & power 
was much reduced according to the patient. It took almost 6 months to improve back to normal again after a hospital 
treatment (diagnosed as MS patient about 7 years ago & was treated in hospital as accordingly but not recovered 
according to patient’s history). Now, she presented to us with the above stated symptoms for the last 2 months which 
are worsening each day. There was no other significant medical history of any other disease previously but she had 2 
cesarean sections for both of her deliveries. In her personal history she denied of taking any kind of drugs, smoking or 
alcohol intake. Her sleep is normal but appetite is decreased & there is urinary & fecal incontinence.Her family history 
was normal and insignificant regarding  neurological diseases. Her physical examination revealed normal vitals 
state(Pulse80/min, B.P130/70, Temp98.6F & there was no lyphmadenophathy, jaundice, edema or cyanosis in body). 
The Mental state examination was evaluated & found completely normal as she was alert, attentive, and oriented in 
time, place & person. Speech was clear and fluent with good repetition, comprehension, and naming.Eye examination 
showed bilateral optic disc atrophy & there was no light perception(fixed dilated pupils) but movements were normal & 
there was no sign of ptosisor deviation of eyes. CN V examination showed facial sensation was intact to pinprick in all 
3 divisions bilaterally & corneal responses were intact. Similarly,
TABLE NO.1 EXAMIANTION OF MOTOR SYSTEM  
All other systems including cardiovascular, respiratory & abdominal were normal & there was no clinical 
symptomatology /findings found related to these systems (except urinary incontinence). Her lab investigations showed 
leucocytosis (12500/mm3), raised ESR levels(70mm/hr) & CRP levels(4.5mg/l). Other investigations like renal 
function tests, liver function tests, serum electrolytes & serum glucose were in normal limits. ECG & Echocardiography 
was done and it was also normal showed nothing of peculiar importance. MRI brain & spine(with contrast) was advised 
to the patient for Bilteral optic neuritis and TM which favors NMO more than MS but MRI brain was unequivocal & 
showed no lesions in brain infact there was Longitudinally extensive transverse myelitis (large area of abnormal signals 
noted  in the spinal cord at the level of T2 through T6 vertebrae with unrestricted diffusion & cord thinning).In our 
patient, a MRI done 5-6 years back had lesion around 3rd ventricle that are totally vanished now (normal MRI Brain). 
This led to the  diagnosis of NMO as she was meeting the diagnostic criteria of NMO[table.2]1 so, the aquaporin-4 
antibody(AQP4-Ab) was sent for the confirmation of Devic’s disease & it came back positive(1385.5U/ml)ref 
range(0.0-0.3U/ml). Thus this established our diagnosis of NMO as per its criteria (100%) over Multiple Sclerosis1. As, 
she presented to us with an acute phase of NMO so we started her on IV glucocorticoids (methyl-prednisolone) 500mg 
diluted once a day for 7 days, injection Enoxaparin sodium(40mg) once a day for the prophylaxis of deep venous 
thrombosis, injection ceftrioxone 1gm(for leucocytosis) & IV proton pump inhibitors. She remained  admitted in 
hospital for 8 days and then was discharged on immunosuppressive drug (tab. Azathioprine) for the prevention of 
future relapses of this disease. The displaying side effects were very little enhanced aside from urinary/fecal 
incontinence and she was likewise exhorted physiotherapy (for development of leg weakness) & she requested line up 
following multi month with 2 weekly rehashing of renal and liver capacity tests.
DISCUSSION: 
Devic’s disease or Neuromyelitis optica is an inflammatory & demyelinating disease of central nervous system1 having 
typical cardinal clinical characteristics i.e. Longitudinally extensive transverse myelitis & optic neuritis. The  previously 
stated features can be present at the same time or can be separated by many years. Diseases like multiple sclerosis 
,malignancy , neurosarcoidosis, infections, inflammation, idiopathic optic neuritis, idiopathic transverse myelitis or 
vascular diseases can mimic NMOSD by involving optic nerve or spinal cord. NMO and MS  share some phenotypic 
features & it should be differentiated from each other as they have different treatment modalities.(Table no.3)9.So 
optic involvement, no MRI brain lesions, spinal cord lesions >3segments and positive AQP4-Ab, were all Confirmatory 
of NMO. Differentiation of NMO from MS is important as interferons, fingolimod and natalizumab are ineffective or may 
aggravate NMO10. Idiopathic optic neuritis is excluded from differentials because it is usually unilateral with impaired 
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color vision but improvement of visual acuity with 3 weeks to 1year11.In our case, relapsing disease course,bilateral 
optic nerve involvement, poor visual outcome & transverse myelitis causing  paraplegia with urinary incontinence are 
the prominent features.
Table2 International consensus diagnostic criteria for Neuromyelitis Optica(2015) [1]
Table3 Comparison between MS & NMO9 .
According to the International consensus diagnostic criteria for Neuromyelitis Optica (2015)[table no.2]1 our patient 
has positive aquaporin-4 antibody(AQP4-Ab) and has 2 core clinical characteristics which confirms the diagnosis. 
NMO can be monophasic  i.e. a single episode with permanent remission or it can result in a relapsing disease which 
is present in 85-90% of the cases. The characteristics of both monophasic & relapsing NMO have quite 
dissimilarities.[table no.4]6
Table 4 Characteristics of monophasic and relapsing Neuromyelitis optica[6]
Identification of NMO is by neurological examination, blood test(positive anti AQP4-Ab),MRI,CSF findings .Here 
auto-antibodies develop against aquaporin 4(water channel protein) and there is disruption of blood–brain barrier, 
glutamate homeostasis impairment and induction of necrotic cell death by AQP4-Ab-positive serum10.this leads to 
astrocyte damage, perivascular and spinal cord inflammation and cavitations of optic nerve12.AQP4-IgG is 
73%sensitive and 91% specific in NMO12.NMO is a disease with severe sequelae so acute and maintenance therapy 
both are very important. In acute cases, pulse steroid therapy is given. If response is not good, IVIG and 
plasmapheresis may play a role12for long term relapse prevention, Azathioprine with oral steroids and mycophenolate 
mofetil with oral steroids are given13.For refractory cases, Rituximab and mitoxantrone show some efficacy13.There 
is no role of interferons10.In our case patient showed improvement with 7 days IV steroids and then discharged on 
Azathioprine as maintenance therapy. As we had advised patient for follow up & she came with same presentation at 
which she was discahrged after 1 month. We ran all her baseline investigations(Cbc, Rft, Lft, Serum electrolytes & 
urine/RE) & they came in normal parameters. To sum up, 5 year survival of NMO is as low as 68%13.
 
CONCLUSION:
 
After all this inferencing we emphasize early and right diagnosis with management of acute and chronic phase as 
damage & disability is slowly cumulative by recurrent attacks that damage new areas of myelin. we also need attention 
to significance of strict patient-physician collaboration in follow-up-periods. 
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ABSTRACT:
Devic’s disease or syndrome also known as Neuromyelitis optica (NMO) which is a demyelinating central nervous 
system (immune-mediated) ailment that predominantly targets the optic nerves and spinal cord. NMO-IgG 
seropositivity & longitudinally extensive  spinal-cord lesions typically represents the Devic’s disease & differentiates it 
from Multiple Sclerosis (MS).Treatment for NMO is based upon its presentation such as for acute phase(steroids, IVIG 
etc), prevention of relapse (steroid sparing immunosuppression etc) and symptom based therapy (e.g spasticity etc). 
Here, we present a case of NMO in a young female (26 years old), married patient who presented to us with total vision 
loss, urinary & fecal incontinence & paraplegia. She was being treated as a case of Multiple Sclerosis (MS) several 
years ago but we further investigated & found NMO-IgG seropositivity and other findings in the history that conforms 
the diagnostic criteria of NMOSD for this patient. Furthermore, the patient was treated with IV glucocorticoids for its 
acute phase of disease & sent home when symptoms of transverse myelitis improved.
KEYWORDS:  Neuromyelitis optica (NMO), Multiple Sclerosis (MS), Neuromyelitis optica-immunoglobulinG(NMO-IgG), 
aquaporin-4 antibody(AQP4-Ab), Cranial nerve(CN)
INTRODUCTION:
Neuromyelitis optica (a demyelinating  disease of central nervous system)1was described by Albutt in 1870 and after 
two decades Devic narrated its clinical features i.e. acute transverse myelitis &optic neuritis. The incidence 
&prevalence of NMO is quite low as it is a rare disease to be found in general population. The worldwide incidence of 
this disease is 0.053 to 0.40 per 100,000, while the prevalence is ranged from 0.52 to 4.4 per 100,0002 .This 
disease (NMO) is more to be found among Asians, Blacks & Indian populations & it is estimated that the prevalence 
in Northwest of England is approximately  0.72 per 100,0003 & in Japan is 14 per 100,0004,5 While the mean age for 
NMO is 40 years(approx.) but it could be present among young ones6,7 & there is a female predominance with a female 
to male ratio of3:1. Neuromyelitis optica-immunoglobulin is a highly specific & sensitive auto antibody for diagnosis of 
NMO which binds to the aquaporin-4 (AQP4); channels that regulate water homeostasis in the CNS4,7,8. 
 
CASE REPORT:
A 26 year old female, married having two children (a girl & boy) presented to us with bilateral vision loss (total 
blindness) for the last 6 years(2012-18), paraplegia for the last 2 months(2018) with urinary & fecal incontinence 
(on/off). There was sudden loss of vision in the right eye with extreme pain  9 years ago(2010), followed by other eye 
vision loss after 3 years of the previous one but this time it was a gradual loss of sight over 2-3 months. In the same 
year she had her first episode of leg weakness (left) & urinary incontinence which was gradual & slow in nature but 
improved after 1 month of hospital treatment (drugs included steroids). After 3 years(2013) she felt moderate 
weakness in both upper limbs and left leg weakness with urinary & fecal incontinence. It was gradual in onset & power 
was much reduced according to the patient. It took almost 6 months to improve back to normal again after a hospital 
treatment (diagnosed as MS patient about 7 years ago & was treated in hospital as accordingly but not recovered 
according to patient’s history). Now, she presented to us with the above stated symptoms for the last 2 months which 
are worsening each day. There was no other significant medical history of any other disease previously but she had 2 
cesarean sections for both of her deliveries. In her personal history she denied of taking any kind of drugs, smoking or 
alcohol intake. Her sleep is normal but appetite is decreased & there is urinary & fecal incontinence.Her family history 
was normal and insignificant regarding  neurological diseases. Her physical examination revealed normal vitals 
state(Pulse80/min, B.P130/70, Temp98.6F & there was no lyphmadenophathy, jaundice, edema or cyanosis in body). 
The Mental state examination was evaluated & found completely normal as she was alert, attentive, and oriented in 
time, place & person. Speech was clear and fluent with good repetition, comprehension, and naming.Eye examination 
showed bilateral optic disc atrophy & there was no light perception(fixed dilated pupils) but movements were normal & 
there was no sign of ptosisor deviation of eyes. CN V examination showed facial sensation was intact to pinprick in all 
3 divisions bilaterally & corneal responses were intact. Similarly,
TABLE NO.1 EXAMIANTION OF MOTOR SYSTEM  
All other systems including cardiovascular, respiratory & abdominal were normal & there was no clinical 
symptomatology /findings found related to these systems (except urinary incontinence). Her lab investigations showed 
leucocytosis (12500/mm3), raised ESR levels(70mm/hr) & CRP levels(4.5mg/l). Other investigations like renal 
function tests, liver function tests, serum electrolytes & serum glucose were in normal limits. ECG & Echocardiography 
was done and it was also normal showed nothing of peculiar importance. MRI brain & spine(with contrast) was advised 
to the patient for Bilteral optic neuritis and TM which favors NMO more than MS but MRI brain was unequivocal & 
showed no lesions in brain infact there was Longitudinally extensive transverse myelitis (large area of abnormal signals 
noted  in the spinal cord at the level of T2 through T6 vertebrae with unrestricted diffusion & cord thinning).In our 
patient, a MRI done 5-6 years back had lesion around 3rd ventricle that are totally vanished now (normal MRI Brain). 
This led to the  diagnosis of NMO as she was meeting the diagnostic criteria of NMO[table.2]1 so, the aquaporin-4 
antibody(AQP4-Ab) was sent for the confirmation of Devic’s disease & it came back positive(1385.5U/ml)ref 
range(0.0-0.3U/ml). Thus this established our diagnosis of NMO as per its criteria (100%) over Multiple Sclerosis1. As, 
she presented to us with an acute phase of NMO so we started her on IV glucocorticoids (methyl-prednisolone) 500mg 
diluted once a day for 7 days, injection Enoxaparin sodium(40mg) once a day for the prophylaxis of deep venous 
thrombosis, injection ceftrioxone 1gm(for leucocytosis) & IV proton pump inhibitors. She remained  admitted in 
hospital for 8 days and then was discharged on immunosuppressive drug (tab. Azathioprine) for the prevention of 
future relapses of this disease. The displaying side effects were very little enhanced aside from urinary/fecal 
incontinence and she was likewise exhorted physiotherapy (for development of leg weakness) & she requested line up 
following multi month with 2 weekly rehashing of renal and liver capacity tests.
DISCUSSION: 
Devic’s disease or Neuromyelitis optica is an inflammatory & demyelinating disease of central nervous system1 having 
typical cardinal clinical characteristics i.e. Longitudinally extensive transverse myelitis & optic neuritis. The  previously 
stated features can be present at the same time or can be separated by many years. Diseases like multiple sclerosis 
,malignancy , neurosarcoidosis, infections, inflammation, idiopathic optic neuritis, idiopathic transverse myelitis or 
vascular diseases can mimic NMOSD by involving optic nerve or spinal cord. NMO and MS  share some phenotypic 
features & it should be differentiated from each other as they have different treatment modalities.(Table no.3)9.So 
optic involvement, no MRI brain lesions, spinal cord lesions >3segments and positive AQP4-Ab, were all Confirmatory 
of NMO. Differentiation of NMO from MS is important as interferons, fingolimod and natalizumab are ineffective or may 
aggravate NMO10. Idiopathic optic neuritis is excluded from differentials because it is usually unilateral with impaired 
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color vision but improvement of visual acuity with 3 weeks to 1year11.In our case, relapsing disease course,bilateral 
optic nerve involvement, poor visual outcome & transverse myelitis causing  paraplegia with urinary incontinence are 
the prominent features.
Table2 International consensus diagnostic criteria for Neuromyelitis Optica(2015) [1]
Table3 Comparison between MS & NMO9 .
According to the International consensus diagnostic criteria for Neuromyelitis Optica (2015)[table no.2]1 our patient 
has positive aquaporin-4 antibody(AQP4-Ab) and has 2 core clinical characteristics which confirms the diagnosis. 
NMO can be monophasic  i.e. a single episode with permanent remission or it can result in a relapsing disease which 
is present in 85-90% of the cases. The characteristics of both monophasic & relapsing NMO have quite 
dissimilarities.[table no.4]6
Table 4 Characteristics of monophasic and relapsing Neuromyelitis optica[6]
Identification of NMO is by neurological examination, blood test(positive anti AQP4-Ab),MRI,CSF findings .Here 
auto-antibodies develop against aquaporin 4(water channel protein) and there is disruption of blood–brain barrier, 
glutamate homeostasis impairment and induction of necrotic cell death by AQP4-Ab-positive serum10.this leads to 
astrocyte damage, perivascular and spinal cord inflammation and cavitations of optic nerve12.AQP4-IgG is 
73%sensitive and 91% specific in NMO12.NMO is a disease with severe sequelae so acute and maintenance therapy 
both are very important. In acute cases, pulse steroid therapy is given. If response is not good, IVIG and 
plasmapheresis may play a role12for long term relapse prevention, Azathioprine with oral steroids and mycophenolate 
mofetil with oral steroids are given13.For refractory cases, Rituximab and mitoxantrone show some efficacy13.There 
is no role of interferons10.In our case patient showed improvement with 7 days IV steroids and then discharged on 
Azathioprine as maintenance therapy. As we had advised patient for follow up & she came with same presentation at 
which she was discahrged after 1 month. We ran all her baseline investigations(Cbc, Rft, Lft, Serum electrolytes & 
urine/RE) & they came in normal parameters. To sum up, 5 year survival of NMO is as low as 68%13.
 
CONCLUSION:
 
After all this inferencing we emphasize early and right diagnosis with management of acute and chronic phase as 
damage & disability is slowly cumulative by recurrent attacks that damage new areas of myelin. we also need attention 
to significance of strict patient-physician collaboration in follow-up-periods. 
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